Positive 12 month data for EligHTN RDS in Hypertension-St Jude Medical

St. Jude Medical has announced 12-month outcome data from the EnligHTN III study, which demonstrated a continuation of safe, rapid and effective treatment with the next-generation EnligHTN Renal Denervation System for patients with drug-resistant, uncontrolled Hypertension. The EnligHTN III study is an international, non-randomized clinical trial that followed device performance and assessed outcomes at six centers through twelve months of follow-up for 37 eligible patients.

Twelve-month EnligHTN III data showed an average office systolic blood pressure reduction of 23 mmHg points, plus an average ambulatory systolic blood pressure reduction of 10 mmHg points. In addition, 78 percent of patients responded to the therapy, which is defined as a blood pressure reduction of at least 10 mmHg. Data were presented during the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.